How a telehealth prescription actually happens
Most weight-loss telehealth runs asynchronously: you fill in a form, a licensed clinician reads it later, and a prescription goes to a pharmacy you were never told the name of. That is legal and it is not inherently worse than an office visit. What matters is which parts of it a company tells you about, and the FDA has published a short list of the parts that go wrong.
What this comes down to
- The clinician is real and licensed in your state, but you may never speak to one — an asynchronous review of a questionnaire is the norm, not the exception.
- The FDA publishes eight telehealth red flags for consumers. Three of them are about the label on the box you receive.
- Compounded drugs should only be used when an approved drug cannot meet the need, which is the FDA's own framing and is not how most of this market is sold.
- The FDA can act on a compounder's promotional claims. Prescription drug promotion has to be truthful, non-misleading and accurate.
What the steps actually are
- A questionnaire. Height, weight, conditions, medications, sometimes a photo. This is the medical history the prescription is written from, so what it asks about is what the clinician gets to see.
- A clinician review. Someone licensed in your state reads the form, usually without speaking to you. Some companies require a video call, some offer one, some do neither.
- A prescription to a pharmacy. For a compounded product, this is where the compounder enters the story — and for a lot of companies, where the story stops being told.
- A shipment, on a subscription. The medication and the clinical service are frequently billed separately, which is also where the headline price stops matching the charge.
Reviewing a questionnaire without a live conversation is ordinary practice for many conditions, and a prescriber doing it still carries the license and the liability. The honest criticism is narrower: a form only surfaces what it asks about, so a short intake is a thin history, and a company competing on how fast it can approve you has an incentive to keep the form short.
The FDA's own red-flag list
Written specifically for people buying GLP-1s from telehealth platforms, and short enough to check a company against in about two minutes[1]. A company is a warning sign if it:
- claims the compounded drug is the same as an FDA-approved drug
- offers medicine at deep discounts or prices that seem too good to be true
- sends medicine that looks different from what you received before or from the website photo
- ships in packaging that is broken, damaged, or missing instructions for use
- does not require a screening and prescription by a licensed doctor before providing medicine
- has no licensed doctor available to answer questions after the medicine arrives
- makes spelling errors on the label, or prints an incorrect pharmacy address
- names a pharmacy on the label that you think might not be real
That last pair is not hypothetical. The agency says it is aware of fraudulent compounded semaglutide and tirzepatide whose labels name compounding pharmacies that do not exist, and others naming a real licensed pharmacy that did not make the product[1].
Who is actually responsible for what
| Party | What it is responsible for |
|---|---|
| The prescriber | The clinical decision, under a license issued by your state's board |
| A 503A pharmacy | Making the drug for you. Overseen day to day by the state board of pharmacy, not by the FDA, and not subject to manufacturing regulations |
| A 503B outsourcing facility | Making the drug in batches, subject to current good manufacturing practice and inspected by the FDA on a risk-based schedule |
| The telehealth company | The offer, the promotion and the billing. Its promotional claims about a prescription drug must be truthful, non-misleading and accurate |
| The FDA | The approval process — which a compounded drug never went through |
Read from the FDA's compounding questions and answers, September 2025.
The agency states plainly that consumers buying compounded drugs through online pharmacies and telehealth platforms may not know the identity of the compounder that produced the drug, including whether it meets appropriate quality standards and is appropriately licensed[2]. That is not a warning about a bad actor. It is a description of the normal state of affairs, which is why “which pharmacy” is the question we ask of every company we grade.
The sentence nobody puts in the ad
“Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.”
[1]
That is the FDA's framing of what compounding is for, and it sits awkwardly beside a market that sells compounded GLP-1s to anyone who fills in a form and can't afford the brand. Cost is a real barrier and pretending otherwise helps nobody. But a company describing a compounded product as equivalent to the brand is doing something the agency lists first among its red flags, and what compounded actually means is worth reading before you accept the comparison.
What we check, and what we can't
Our read of a company is a read of what it publishes: whether the price is findable, whether a pharmacy is named, who prescribes, which states it serves, and what happens if you stop. We finish the intake ourselves when a price is buried — 8 of the 150 price records here came out of one. When an intake offers a peptide alongside the GLP-1, the extra check is whether the FDA has published a safety finding about it[3],[4]. How we grade sets out what moves a letter. What no reader-facing audit can see is the quality of the clinical review itself, and we don't pretend to grade it.
Questions people actually ask
Is a telehealth prescription for a GLP-1 legitimate?
If a clinician licensed in your state wrote it after reviewing your information, yes. What varies enormously is how much information that review was based on and whether the product dispensed is an approved drug or a compounded one.
Do I have to talk to a doctor to get a prescription?
Often not. Asynchronous review of a questionnaire is standard across this market. The FDA's red-flag list draws the line elsewhere: the warning sign is a company that does not require a screening and prescription by a licensed doctor at all.
How do I find out which pharmacy is making my medication?
Ask before you pay, and read the label when it arrives. The FDA notes that people buying through telehealth platforms frequently do not know who compounded their drug, and it has warned about labels naming pharmacies that do not exist.
What should I do if my shipment arrives warm?
Do not use it. Injectable GLP-1 drugs require refrigeration, and the FDA has received complaints about compounded products arriving warm or with inadequate ice packs, which can affect the drug's quality.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026. Source · Document dated September 2026The FDA publishes eight telehealth red flags for consumers; states that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug; reports fraudulent compounded products labeled with pharmacies that do not exist or that did not make the product; and warns about shipments arriving warm or with inadequate refrigeration.
- Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025State boards have primary day-to-day oversight of 503A pharmacies; outsourcing facilities are subject to current good manufacturing practice and inspected by the FDA on a risk-based schedule; consumers buying compounded drugs through telehealth platforms may not know the identity of the compounder; prescription drug promotion by compounders must be truthful, non-misleading and accurate.
- The Telehealth Graded price record. Telehealth Graded, 2026. Source · The count of prices read first-hand, and the count of those that required completing an intake, are computed at build time from the site's own capture records.
- Substances in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026. Source · Document dated April 2026The FDA maintains a published list of bulk substances it has identified significant safety risks for, which is the check to run on any peptide a telehealth intake offers alongside a GLP-1.